Ethnobridging

Ethnobridging Clinical Development

With biopharmaceutical markets in Asia being some the largest in the world and inclusion of Asian countries in global drug development strategies and registration, the Asia Pacific region has become increasingly important in recent years. Global companies are collecting Japanese, Chinese, Taiwanese, and Korean early phase data in clinical development to fulfill the following goals:

  • Further portfolio value in new markets
  • Risk Mitigation (See safety / efficacy signals in populations earlier)
  • Japan development (fast track)
  • Use data for local partnering strategies in Asia
  • Facilitate the inclusion of Asian countries in global trials
  • Use data for drug registration in the region
  • Use data for local partnering strategies in Asia

Integrium is experienced conducting ethnobridging trials in our phase I facility in Irvine, California. Over the past 5 years, our team has successfully conducted various ethnobridging studies, recruiting and enrolling Japanese, Chinese, Taiwanese, and Korean patients and supporting submission data to local authorities. Our team includes participant recruiters and clinical personnel fluent in various Asian languages.

Integrium’s clinical unit is located in one of the largest first generation Asian communities in the world.

For more information, please email us at: emcgilvreay@integrium.com